Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clopidogrel efficacy by CYP2C19 genotype with thromboelastography guidance
ChiCTR1800015314Phase 4Recruiting
- Sponsor
- Southern Medical University
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of clopidogrel in Ischaemic cerebral disease, transient ischaemic attack (TIA) and ischemic stroke (2 arms), sponsored by Southern Medical University. Primary endpoint: ADP and AA-induced platelet inhibition rates. Started Mar 2018; status: recruiting.
02
Drugs
clopidogrel
03
Conditions
Ischaemic cerebral diseasetransient ischaemic attack (TIA)ischemic stroke
Beyond the preview
Go deeper on ChiCTR1800015314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015314.